Download Novel regulatory S/MAR element for recombinant protein expression

Novel regulatory S/MAR element for recombinant protein expression
in mammalian cells
Reference Number: 02-00289
Challenge
For the production of proteins with pharmaceutical and industrial impact in
mammalian cell lines various approaches are used including gene transfer
technologies. The use of viral vectors for gene transfer is restricted by
major limiting factors such as the occurrence of immune response,
interference with cellular integrity or a potential induction of mutagenesis in
the host genome. A possibility of decreasing the risks associated with viral
vector mediated gene transfer is the application of transient instead of
stable transfection. However, protein production based on transient
transfection is less efficient. Therefore improvement of expression systems
is needed to increase efficiency and safety of the production of proteins of
industrial interest.
Technology
The presented technology provides a newly discovered regulatory
Scaffold/Matrix-Attachment (S/MAR) element, namely the modulator and
unique (MUR)-region of the Cytomegalovirus (CMV) immediate early
promoter/enhancer, for the use in vectors for the recombinant expression of
proteins in mammalian cells. The new CMV S/MAR regulatory element can
optionally be used in vectors that are (1) episomally replicating, (2)
integrated into the host genome, or (3) present as a minicircle expression
vector for stable or transient expression. When placed into a specific vector
location the new CMV S/MAR regulatory element allows increasing and
extending both the productivity of transiently as well as stably transfected
cells. Thus, in stably transfected cells an up to 38-fold increase of gene
expression rates was obtained, while in transiently transfected cells the
rates increased by factor 4, indicating a broad applicability of the new CMV
S/MAR regulatory element for a variety of different mammalian expression
systems.
Commercial Opportunity
The technology is offered for co-development or in-licensing.
Developmental Status
Expression data obtained in a number of standard cell lines for protein
expression, such as HEK293, NIH3T3, BHK etc. for model/indicator proteins
(GFP/Luciferase) available.
Patent Situation
Priority filed in January 2011 (EP11151186). International patent application
filed in January 2012 (WO 2012 098100). European patent application
pending.
Course of d2EGFP expression in HEK293,transiently
transfected with CMV S/MAR containing or CMV
S/MAR less minicircles.
Licensing Contact
Dr Sabina Heim
Technology Manager
T: +49 531 618120-90
F: +49 531 618120-98
[email protected]
Ascenion GmbH
Herzogstraße 64
D-80803 München
T: +49 89 318814-0
F: +49 89 318814-20
[email protected]
www.ascenion.de
Berlin
Braunschweig
Hamburg
Hanover
Munich
Neuherberg
Powered by TCPDF (www.tcpdf.org)